High frequency of aberrant p16(INK4A) expression in human breast cancer

American Journal of Pathology

Volumn 149, Issue 1, 1996, Pages 15-20

  Geradts, Joseph ^a   Wilson, Patrick A ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P21; RETINOBLASTOMA PROTEIN; TUMOR MARKER;

ARTICLE; BREAST CARCINOMA; CELL CYCLE; CONTROLLED STUDY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL;

BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; CARRIER PROTEINS; CELL DIVISION; CYCLIN-DEPENDENT KINASE INHIBITOR P16; ENZYME INHIBITORS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; RETINOBLASTOMA PROTEIN; RETROSPECTIVE STUDIES;

EID: 0029901708     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. INK4 protein is restricted to the subset of lung cancer lines that retains wildtype RB. Oncogene 1994, 9:3375-3378
2. INK4 cyclin dependent kinase inhibitor in malignant mesothelioma. J Natl Cancer Inst 1995, 87:1870-1875
3. Caldas C, Hahn SA, daCosta LT, Redston MS, Schutte M, Seymore AB. Weinstein CL, Hruban RH, Yeo CJ, Kern SE: Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat Genet 1994, 8:27-32
4. Schmidt EE, Ichimura K, Reifenberger G, Collins VP: CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas. Cancer Res 1994, 54:6321-6324
5. T'Ang A, Varley JM, Chakraborty S, Murphree AL, Fung YT: Structural rearrangement of the retinoblastoma gene in human breast carcinoma. Science 1988, 243: 263-266
6. Varley JM, Armour J, Swallow JE, Jeffreys AJ, Ponder BAJ, T'Ang A, Fung YT, Brammar WJ, Walker RA: The retinoblastoma gene is frequently altered leading to loss of expression in primary breast tumours. Oncogene 1989, 4:725-729
7. Borg A, Zhang QX, Alm P, Olsson H, Sellberg G: The retinoblastoma gene in breast cancer: allele loss is not correlated with loss of gene expression Cancer Res 1992, 52:2991-2994
8. Berns E, DeKlein A, van Putten W, van Staveren IL, Bootsma A, Klun J, Foekens JA: Association between RB-1 gene alterations and factors of favourable prognosis in human breast cancer, without effect on survival. Int J Cancer 1995, 64:140-145
9. ink4) in human breast carcinomas. Cancer Res 1994, 54:5262-5264
10. Brenner AJ, Aldaz CM: Chromosome 9p allelic loss, and p16/CDKN2 in breast cancer, and evidence of p16 inactivation in immortal breast epithelial cells. Cancer Res 1995, 55:2892-2895
11. Berns EMJJ, Klijn JGM, Smid M, van Staveren IL, Gruis NA, Foekens JA: Infrequent CDKN2 (MTS1/p16) gene alterations in human primary breast cancer. Br J Cancer 1995, 72:964-967
12. Liu Q, McClure M, Frye C, Weaver-Feldhaus J, Gruis NA, Eddington K, Allalunis-Turner MJ, Skolnick MH, Fujimura FK, Kamb A: CDKN2 (MTS1) tumor suppressor gene mutations in human tumor cell lines. Oncogene 1995, 10:1060-1067
13. Quesnel B, Fenauz P, Philippe N, Fournier J Bonneterre J, Preudhomme C, Peyrat JP: Analysis of p16 gene deletion and point mutation in breast carcinoma. Oncogene 1995, 10:351-353
14. Rush EB, Abouezzi Z, Borgen PI, Anelli A: Analysis of MTS1/CDK4 in female breast carcinomas. Cancer Lett 1995, 89:223-226
15. INK4A in archival human solid tumors: correlation with retinoblastoma protein expression. Cancer Res 1995, 55:6006-6011
16. Elston CW, Ellis IO: Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long term follow-up. Histopathology 1991, 19:403-410
17. Wen SF, Nodelman M, Nared-Hood K, Duncan J, Geradts J, Shepard HM: Retinoblastoma protein monoclonal antibodies with novel characteristics. J Immunol Methods 1994, 169:231-240
18. Geradts J, Kratzke RA, Crush-Stanton S, Wen SF, Lincon SE: Wild type and mutant retinoblastoma protein in paraffin sections. Mod Pathol 1996, 9:339-347
19. Geradts J, Hu S, Lincon CE, Benedict WF, Xu H: Aberrant RB gene expression in routinely processed archival tumor tissues determined by three different anti-RB antibodies. Int J Cancer 1994, 58:161-167
20. Cairns P, Polascik TJ, Eby Y, Tokino K, Califano J, Merlo A, Mao L, Herath J, Jenkins R, Westra W, Rutter JL, Buckler A, Gabrielson E, Tockman M, Cho KR, Hedrick L, Bova GS, Isaacs W, Koch W, Schwab D, Sidransky D: Frequency of homozygous deletion at p16/CDKN2 in primary human tumours. Nat Genet 1995, 11:210-212
21. Herman JG, Merlo A, Mao L, Lapidus RG, Issa JJ, Davidson NE, Sidransky D, Baylin SB: Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res 1995, 55:4525-4530
22. INK4. Cancer Res 1994, 54:5816-5820
23. Xu H, Hu S, Benedict WF: Lack of nuclear RB protein staining in G0/middle G1 cells: correlation to changes in total RB protein level. Oncogene 1991, 6:1139-1146
24. Reed JA, Loganzo F Shea CR, Walker GJ, Flores JF, Glendening JM, Bogdany JK, Shiel MJ, Haluska FG, Fountain JW, Albino AP: Loss of expression of the p16/cyclin-dependent kinase inhibitor 2 tumor suppressor gene in melanocytic lesions correlates with invasive stage of tumor progression. Cancer Res 1995, 55:2713-2718